Tyra Biosciences Revenue vs. Current Valuation

TYRA Stock  USD 15.83  0.47  3.06%   
Based on Tyra Biosciences' profitability indicators, Tyra Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Tyra Biosciences' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
0.0
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Tyra Biosciences' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Capex To Depreciation is expected to grow to 3.95, whereas Book Value Per Share is forecasted to decline to 2.85.
For Tyra Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tyra Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tyra Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tyra Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tyra Biosciences over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.61)
Return On Assets
(0.20)
Return On Equity
(0.29)
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Tyra Biosciences Current Valuation vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Tyra Biosciences's current stock value. Our valuation model uses many indicators to compare Tyra Biosciences value to that of its competitors to determine the firm's financial worth.
Tyra Biosciences is currently under evaluation in revenue category among its peers. It is currently regarded number one company in current valuation category among its peers . At present, Tyra Biosciences' Total Revenue is projected to stay steady based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tyra Biosciences' earnings, one of the primary drivers of an investment's value.

Tyra Revenue vs. Competition

Tyra Biosciences is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 281.17 Million. Tyra Biosciences adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.

Tyra Current Valuation vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Tyra Biosciences

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
null
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Tyra Biosciences

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
423.45 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Tyra Current Valuation vs Competition

Tyra Biosciences is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 715.17 Million. Tyra Biosciences totals roughly 423.45 Million in current valuation claiming about 59% of equities under Health Care industry.

Tyra Biosciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Tyra Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tyra Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Tyra Biosciences' change in net profit over the period of time. It can combine multiple indicators of Tyra Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income381 K400.1 K
Net Interest Income10.8 M11.4 M
Operating Income-79.9 M-75.9 M
Net Loss-69.1 M-65.7 M
Income Before Tax-69.1 M-65.7 M
Total Other Income Expense Net10.8 M11.4 M
Net Loss-49.8 M-47.3 M
Net Loss-69.1 M-65.7 M
Income Tax Expense-3.2 M-3.1 M
Interest Income10.8 M11.4 M
Non Operating Income Net Other4.1 M4.3 M
Change To Netincome12.2 M12.8 M
Net Loss(1.62)(1.70)
Income Quality 0.73  0.64 
Net Income Per E B T 0.93  1.08 

Tyra Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Tyra Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tyra Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tyra Biosciences' important profitability drivers and their relationship over time.

Use Tyra Biosciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tyra Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tyra Biosciences will appreciate offsetting losses from the drop in the long position's value.

Tyra Biosciences Pair Trading

Tyra Biosciences Pair Trading Analysis

The ability to find closely correlated positions to Tyra Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tyra Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tyra Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tyra Biosciences to buy it.
The correlation of Tyra Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tyra Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tyra Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tyra Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Tyra Biosciences position

In addition to having Tyra Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Macroaxis Index Thematic Idea Now

Macroaxis Index
Macroaxis Index Theme
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:
Check out World Market Map.
For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
To fully project Tyra Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Tyra Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Tyra Biosciences' income statement, its balance sheet, and the statement of cash flows.
Potential Tyra Biosciences investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Tyra Biosciences investors may work on each financial statement separately, they are all related. The changes in Tyra Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tyra Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.